Resistance of multidrug-resistant strains of Mycobacterium tuberculosis from the Archangel oblast, Russia, to second-line anti-tuberculosis drugs.
Multidrug-resistant tuberculosis has become common all over the world, necessitating the inclusion of second-line drugs in treatment regimens. In the present study, the susceptibility of a selection of multidrug-resistant strains of Mycobacterium tuberculosis isolated in the Archangel oblast, Russia, to second-line anti-tuberculosis drugs was analysed. Susceptibility testing of 77 Mycobacterium tuberculosis strains was performed by the Bactec method using the following recommended drug concentrations: capreomycin 1.25 microg/ml; ethionamide 1.25 microg/ml; kanamycin 5 microg/ml; and ofloxacin 2 microg/ml. The majority of strains (92.2%) were resistant to ethionamide. High rates of drug resistance were also found for capreomycin (42.9%) and kanamycin (41.6%), while nearly all strains (98.7%) were susceptible to ofloxacin. The high rates of resistance to ethionamide, capreomycin, and kanamycin show the real burden of drug resistance in the region and pose a serious problem for the treatment of patients with multidrug-resistant tuberculosis.
Toungoussova
O S
OS
Department of General Practice and Community Medicine, Faculty of Medicine, University of Oslo, P.O. Box 1130, Blindern, 0317, Oslo, Norway. o.s.toungoussova@samfunnsmed.uio.no
Mariandyshev
A O
AO
Bjune
G
G
Caugant
D A
DA
Sandven
P
P
D000995:Antitubercular Agents / Q000494:pharmacology*; D002207:Capreomycin / Q000494:pharmacology; D024901:Drug Resistance, Multiple, Bacterial; D005000:Ethionamide / Q000494:pharmacology; D006801:Humans; D007612:Kanamycin / Q000494:pharmacology; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D015242:Ofloxacin / Q000494:pharmacology; D012426:Russia; D014397:Tuberculosis, Pulmonary / Q000382:microbiology
D000995:Antitubercular Agents; D002207:Capreomycin; D007612:Kanamycin; D015242:Ofloxacin; D005000:Ethionamide
J Infect Dis. 2002 Apr 15;185(8):1197-202
11930334
BMJ. 2003 Mar 15;326(7389):574
12637401
J Clin Microbiol. 2002 Jun;40(6):1930-7
12037045
Int J Tuberc Lung Dis. 2002 May;6(5):406-14
12019916
J Clin Microbiol. 1999 Oct;37(10):3179-86
10488174
Int J Tuberc Lung Dis. 2001 Mar;5(3):213-5
11326818
Clin Infect Dis. 2003 Sep 1;37(5):665-72
12942398
Int J Tuberc Lung Dis. 2000 Dec;4(12 Suppl 2):S194-207
11144553
Lancet. 2002 Jun 8;359(9322):1980-9
12076553
Clin Microbiol Rev. 1995 Oct;8(4):496-514
8665467